DMP1 C-Terminal Mutant Mice Recapture the Human ARHR Tooth Phenotype

Baichun Jiang,1,2* Zhengguo Cao,2,3* Yongbo Lu,2 Carol Janik,4 Stephanie Lauziere,4 Yixia Xie,2 Anne Poliard,5 Chunlin Qin,2 Leanne M Ward,4 and Jian Q Feng2

1Institute of Medical Genetics, Shandong University School of Medicine, Jinan, People’s Republic of China
2Department of Biomedical Sciences, Baylor College of Dentistry, Dallas, TX, USA
3The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, People’s Republic of China
4Departments of Pediatrics and Surgery, Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada
5Inserm UMR S747, Université Paris Descartes 45 rue des Saints-Pères 75006 Paris, France

ABSTRACT

DMP1 mutations in autosomal recessive hypophosphatemic rickets (ARHR) patients and mice lacking Dmp1 display an overlapping pathophysiology, such as hypophosphatemia. However, subtle differences exist between the mouse model and human ARHR patients. These differences could be due to a species specificity of human versus mouse, or it may be that the mutant DMP1 in humans maintains partial function of DMP1. In this study we report a deformed tooth phenotype in a human DMP1 deletion mutation case. Unexpectedly, the deletion of nucleotides 1484 to 1490 (c.1484_1490delCTATCAC, delMut, resulting in replacement of the last 18 residues with 33 random amino acids) showed a severe dentin and enamel defect similar to a dentinogenesis imperfecta (DI) III–like phenotype. To address the molecular mechanism behind this phenotype, we generated delMut transgenic mice with the endogenous Dmp1 gene removed. These mutant mice did not recapture the abnormal phenotype observed in the human patient but displayed a mild rachitic tooth phenotype in comparison with that in the Dmp1-null mice, suggesting that the DI III–like phenotype may be due to an as-yet-undetermined acquired gene modifier. The mechanism studies showed that the mutant fragment maintains partial function of DMP1 such as stimulating MAP kinase signaling in vitro. Last, the in vitro and in vivo data support a role of odontoblasts in the control of fibroblast growth factor 23 (FGF-23) regulation during early postnatal development, although this regulation on Pi homeostasis is likely limited. © 2010 American Society for Bone and Mineral Research.

KEY WORDS: DMP1; ARHR; ODONTOBLAST; FGF-23; HYPOPHOSPHATEMIA

Introduction

Mutations in fibroblast growth factor 23 (FGF23) and PHEX account for approximately 60% of hypophosphatemic rickets with eucalciuria and are associated with abnormalities in dentin and bone.(1) Mutations in the type 2a sodium-phosphate cotransporter lead to hereditary hypophosphatemic rickets with hypercalcemia (HHRH). (2-4) The molecular defects responsible for the remaining hypophosphatemic patients are unknown.

Previously, we reported that Dmp1-null newborns displayed no gross phenotype(7) but developed hypophosphatemia including hypomineralized bone,(8) defects in chondrogenesis,(9) partial failure of predentin maturation into dentin, and expansion of the pulp cavities and root canals during postnatal tooth development.(10) These data support a dual role of DMP1 in both local and systemic regulation of phosphate (Pi) homeostasis.(11,12)

We and others also reported that DMP1 mutations are responsible for autosomal recessive hypophosphatemic rickets (ARHR) in human patients, including bone defects and an increase in fibroblast growth factor 23 (FGF-23) levels (although some of DMP1 mutation patients overlapped with the normal range for FGF-23). (12-14) However, there is a phenotypic difference between human patients (mild) and Dmp1-null mice (severe). These differences could be due to a species specificity of human versus mouse or to the fact that the mutant fragment may maintain partial DMP1 function. Furthermore, few clinical cases of ARHR have been reported so far;
therefore, it is challenging to obtain human cases for pathophysiologic studies.\textsuperscript{(12,13,15)} Thus generation of \textit{DMP1} mutant mouse models based on the human mutations is critical not only for distinguishing these differences but also for molecular pathophysiologic studies of this disorder.

The tooth phenotype in our previously reported ARHR cases\textsuperscript{(12)} has not been reported. \textit{DMP1}, highly expressed in odontoblasts\textsuperscript{(7)} and osteocyte cells,\textsuperscript{(16)} is cleaved into N-terminal and C-terminal fragments,\textsuperscript{(11)} but it is not clear which fragment is functionally critical for bone and tooth formation both in vivo and in vitro.

The goals of this study were (1) to report the \textit{DMP1} mutant tooth phenotype from one of our previously reported clinical cases,\textsuperscript{(12)} (2) to determine the molecular genetics and pathophysiology of \textit{DMP1} mutations through generation and analysis of a mouse model harboring the \textit{DMP1} deletion mutation compared with \textit{Dmp1}-null mice, (3) to understand how the \textit{Dmp1} mutant changes cell signaling in vitro, (4) to determine whether \textit{Dmp1}-null or \textit{Dmp1} delMut mice develop an enamel phenotype, and (5) to test whether odontoblast cells play a role in control of FGF23 expression.

**Materials and Methods**

**Human subjects**

Dental radiographs were obtained from one individual with ARHR owing to the delMut described previously (patient F\textsubscript{1,2}).\textsuperscript{(12)} Patient F\textsubscript{1,2} had unique clinical features that distinguished her from the other hypophosphatemic patients in these kindreds, including global developmental delay and a seizure disorder. To date, it remains unclear whether these additional features are linked to the delMut in \textit{DMP1}; however, their presence in a single patient who has two affected siblings without these features raises the likelihood that they are not part of the ARHR phenotype.

**Generation of mutant \textit{Dmp1} transgenic mice**

A full-length mouse \textit{Dmp1} cDNA was cloned, and 7 nucleotides corresponding to the 1484-1490del mutation of human \textit{DMP1} in ARHR patients\textsuperscript{(12)} were deleted by site-directed mutagenesis using the QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) with primers DMUT-F (GAAACTAA-TAGTTGATGCAACAAA CCCATTGGGGACCAAATG) and DMUT-R (CATCTGGTGCCCACATGGGTGTGTCATCAACTTATGGTTC). For generation of a mutant \textit{Dmp1} transgene, the full-length mouse \textit{Dmp1} cDNA with the 7-nucleotide deletion and an SV40 polyadenylation signal were cloned into a mammalian expression vector\textsuperscript{(17)} (graciously provided by B Kream and A Lichtler, University of Connecticut Health Center, Farmington, CT, USA) containing the 3.6-kb rat type I collagen promoter plus a 1.6-kb intron 1 (Col1a1 promoter) that is highly active in pulp cells, odontoblasts, and osteoblasts, giving rise to the \textit{Col1a1}-mutant \textit{Dmp1} transgene. The transgene was released by Sacl and Sall from the vector backbone and purified for pronuclear injection. Transgenic founders with CD1 background were generated. Three of five independent transgenic lines were used for crossing to \textit{Dmp1}-null mice (see below).

**Target expression of the mutant \textit{Dmp1} transgene in \textit{Dmp1-null} mice**

We have previously described the generation of \textit{Dmp1}-null mice using the lacZ knock-in targeting approach.\textsuperscript{(7)} For expression of the mutant \textit{Dmp1} transgene in \textit{Dmp1-null} mice, \textit{Col1a1}-mutant \textit{Dmp1} transgenic mice were first crossed with heterozygous (HET) \textit{Dmp1}-null mice to generate HET \textit{Dmp1-null} mice with the \textit{Col1a1}-mutant \textit{Dmp1} transgene (\textit{Tg}\textsuperscript{+/−;Dmp1−/−}). These mice were further bred with homozygous \textit{Dmp1-null} mice to generate homozygous \textit{Dmp1-null} mice carrying the mutant \textit{Dmp1} transgene (\textit{Tg}\textsuperscript{−/−;Dmp1−/−}). This mouse line is designated \textit{mutant mouse} (Mut). Since no phenotypic differences between the wild-type and homozygous \textit{Dmp1-null} mice were found,\textsuperscript{(9,10)} the littermate HET \textit{Dmp1} mice were used for control.

The two \textit{Dmp1} transgenic mouse lines\textsuperscript{(18)} \textit{Col1a1P-Dmp1} transgene (under the control of the same promoter as used for driving the mutant \textit{Dmp1} transgene) and \textit{DsppP-Dmp1} transgene (under control of the 6-kb mouse \textit{Dspp} promoter, actively expressed only in late odontoblast cells)\textsuperscript{(19)} were crossed into \textit{Dmp1-null} mice.\textsuperscript{(7)} Samples of three developmental stages (10 days old, 3 weeks old, and 2 months old) were obtained and analyzed for this study. All mice were bred to a CD1 background, an outbred strain for getting closer to the physiologic condition. The animal research has complied with all relevant federal guidelines and institutional policies.

**PCR genotyping**

Genomic DNA was extracted from a tail biopsy and used for genotyping by PCR analysis. Primers p01 (5′-GAGTGCCATCTCTTCAT-GAGGCGGATAGCTGTC-3′) and p02 (5′-CGCGGCTGAAATCATCATGTAAGCCAGGGTGG-3′) were used for detection of the \textit{Dmp1-null} allele (490 bp), and primers p03 (5′-GCCGCTGGAGACATGCA-TAGC-3′) and p04 (5′-CTGGTCTCCTACTCTAGTC-3′) were used for detection of the wild-type allele (421 bp). The primers p05 (5′-CACGGCTTCTGAGAAGACACTG-3′ from \textit{Dmp1} CDNA) and p06 (5′-TGTCCAAAATCTACAATGATCT-3′ from the SV40 polyadenylation signal) were used for detection of the wild-type (WT) or mutant \textit{Dmp1} transgene (337 or 330 bp, respectively).

**High-resolution tooth radiography and micro–computed tomography (μCT)**

The mandible samples from control, \textit{Dmp1-null}, and mutant mice were dissected free of muscle, and the first molars of the maxilla were extracted as described previously.\textsuperscript{(10)} Briefly, fresh mandibles were incubated in lysis buffer (2 × SSC, 0.2% SDS, 10 mM EDTA, and 1 mg/mL protease K) for 1 to 2 days at 55 °C. After the muscles surrounding teeth were digested, the molars were extracted under a dissection microscope. The intact mandibles and first molars then were examined radiographically using a high-resolution radiography system (piXarray 100, Micro Photonics, Allentown, PA, USA). μCT analyses include a low-resolution scan of one hemimandible per animal for overall assessment of shape and structure and a high-resolution (6-μm) scan of a more limited anatomic area (200 slices) in a specified region of interest for detailed 3D
morphometric analyses using a Scanco µCT 35 (Scanco Medical AG, Brütisellen, Switzerland).

Histologic preparation

Mandible specimens from control, Dmp1-null, mutant, and rescued mice were dissected and fixed in 4% paraformaldehyde at 4°C overnight, followed by two different processes: (1) One side specimens were decalcified, dehydrated, and embedded in paraffin and then sectioned for in situ hybridization, hematoxylin and eosin (H&E) staining, and safranin-O staining, and (2) the other side specimens were dehydrated and embedded in methyl methacrylate, and nondecalcified sections were used for dentin formation rate and scanning electron microscopy (SEM).

In situ hybridization

The mouse antisense RNAs for Dmp1, Fgf23, and Phex were used for in situ hybridization, as described previously. Briefly, digoxigenin (DIG)–labeled mouse cRNA probes were prepared by using an RNA Labeling Kit (Roche, Indianapolis, IN, USA). The hybridization temperature was set at 55°C, and the washing temperature was set at 70°C so that endogenous alkaline phosphatase was inactivated. DIG-labeled nucleic acids were detected in an enzyme-linked immunoassay with a specific anti-DIG-AP antibody conjugate and an improved substrate that gives rise to a red signal (Vector, Burlingame, CA, USA) according to the manufacturer’s instructions.

Double fluorochrome labeling

To examine the dentin formation rate, double fluorescence labeling was performed as described previously. Briefly, an alizarin red label (20 mg/kg i.p.; Sigma-Aldrich, St. Louis, MO, USA) was administered to 12-day-old mice, followed by an injection (3 weeks old). The nondecalcified upper mandibles were sectioned, and unstained sections were photographed for double fluorochrome labeling.

Generation of recombinant DMP1 proteins, cell cultures, stains-all staining, and Western blot

The full-length DMP1, C-terminal DMP1, and full-length delMut DMP1 cDNAs were cloned originally into the pcDNA3 vector. The empty pcDNA3 vector, pcDNA3-WT DMP1 vector, and pcDNA3-delMut DMP1 vector, were transfected into 293 cell lines assayed using a Calcium Liquicolor Kit (Stanbio Laboratory) following the manufacturer’s protocol. Serum P levels were measured using a Phosphorus Liqui-UV Kit (Stanbio Laboratory, Boerne, TX, USA). Serum calcium levels were assayed using a Calcium Liquicolor Kit (Stanbio Laboratory) following the manufacturer’s protocol. Serum intact FGF-23 levels were measured using a Phosphorus Liqui-UV Kit (Stanbio Laboratory).

Real-time RTPCR

Newborn primary calvarial and pulp cells were isolated and cultured for 48 hours, followed by real-time RT-PCR for quantitation of Fgf23 mRNA. Briefly, total RNA was extracted by using a Trizol reagent (Invitrogen, Carlsbad, CA, USA). Freshly isolated RNA was reverse transcribed with a Super Script first-strand synthesis system (Invitrogen) following the manufacturer’s recommendations. The resulting cDNA then was subjected to quantitative real-time PCR using 2× Brilliant SYBR QPCR Green Master Mix Reagent (Stratagene, Cedar Creek, TX, USA). The sequences of the primers were for Fgf23, 5′-TACCTGTGCGAGGATCAGC-3′ and 5′-GGCGAAACAGTGTAGGACAG-3′, and for Gapdh, 5′-ACCA-CAGTCCATGCCATCAC-3′ and 5′-TCCACCCACCCTGTTGCTGTA-3′. Three independent measurements per sample were performed. The quantified individual RNA expression levels were normalized to Gapdh.

Serum biochemistry

Ten-day-, 3-week-, and 2-month-old male mice were anesthetized, blood was collected though heart puncture, and serum samples were obtained by precipitation and centrifugation. Serum P, levels were measured using a Phosphorus Liqui-UV Kit (Stanbio Laboratory, Boerne, TX, USA). Serum calcium levels were assayed using a Calcium Liquicolor Kit (Stanbio Laboratory) following the manufacturer’s protocol. Serum intact FGF-23 levels were measured using an FGF-23 ELISA Kit (Kainos Laboratories, Tokyo, Japan), as described previously.

Statistical analysis

Data were expressed as the mean ± SEM. Data were evaluated statistically by ANOVA to test for any differences among the three groups of mice. If significant differences were found by ANOVA, the Bonferroni method of multiple comparisons was used to determine which groups were significantly different from each other. A p value of less than .05 is considered statistically significant.
Results

DMP1 deletion mutation led to DI III-like tooth phenotype

Previously, we reported that the deletion of nucleotides 1484 to 1490 of DMP1 (delMut) resulted in the last 18 amino acids being replaced by 33 nonnative residues. The radiograph of a delMut child at age 3+ showed significantly enlarged pulps and root canals with extremely thin dentin and loss of enamel (Fig. 1B). At age 10, the same child showed a DI III-like phenotype, including the following features: lack of well-mineralized dental enamel, enlarged pulp chamber, and enlarged root canal, which are likely a result of decreased dentin formation as well as malformed tooth shape (Fig. 1B).

The severe tooth phenotype, affecting both dentin and enamel, in the delMut patient raised the following questions: Is the tooth phenotype a primary consequence of the DMP1 mutation or the result of a dominant-negative role of this mutant or other events trigged by the mutation? The simplest way to address this dilemma is to generate a delMut mouse model mimicking the same mutation observed in human patients and to test whether this deletion mutation will recapitulate the same tooth phenotype in mice.

Overexpression of delMut transgene driven by a 3.6-kb Col1a1 promoter in a wild-type background has no apparent phenotype

To generate a delMut mouse model harboring the human DMP1 1484-1490del mutation, we first generated a transgenic mouse harboring a full-length Dmp1 cDNA with the same deletion mutation as observed in the patients under the control of a 3.6-kb Col1a1 promoter, which is highly active in pulp cells, odontoblasts, and osteoblasts. Previously, we have successfully rescued the Dmp1-null tooth phenotypes using the full-length Dmp1 cDNA under the control of the same promoter, thus this promoter might have the proper spatial-temporal characteristics to mimic the endogenous Dmp1 gene expression in teeth. Five independent Col1a1-mutant Dmp1 transgenic lines were obtained, and three independent lines were used for this study. These three lines (2, 11, and 21) have different expression levels (see the RT-PCR data in Supplemental Fig. 1), although none of these lines shows an apparent phenotype (data not shown), excluding a dominant-negative role of this mutant in the WT background. In addition, all three lines in the Dmp1-null background show an identical expression pattern, although only line 2 is shown in Fig. 2A.

Dmp1 mutant mice display abnormalities in dentinogenesis and condyle formation with little change in enamel

Next, we crossed these three independent lines of the delMut mice into the Dmp1-null background. All these independent lines display an identical dentin-defect phenotype (see below), although only one of the mutant lines is presented (line 2). Note that we have previously reported that Dmp1-null mice displayed a partial failure of maturation of predentin into dentin, hypomineralization of the dentin, and expansion of the pulp cavities and root canals during postnatal tooth development.

To determine whether the Dmp1 delMut mice display the same phenotype as the mutant individual, the mutant (Fig. 2, right panels), the Dmp1-null (Fig. 2, middle panels), and the control mice (Fig. 2, left panels) were examined by a combination of radiography, micro-computed tomography (µCT), histology, and a double-labeling assay, as well as backscattered SEM. Like Dmp1-null mice, Dmp1 mutant mice showed a thin dentin and an enlarged pulp cavity and root canal with radiographic and µCT analyses (Fig. 2B, C). Note that the quantitative analysis showed a significant reduction of dentin in the Dmp1-null mice, with p < .05 compared with the control, whereas the reduction in dentin in the mutant is not significantly different from control (Fig. 2C, lower panel).

Importantly, both the µCT image (Fig. 2C) and backscattered SEM images (Fig. 2D) showed identical mineral density and prism structure in control, knockout, and mutant mice. High-resolution 3D µCT images showed that the root dentin is porous in the root canals of both the Dmp1-null and delMut mice (Fig. 2E). H&E staining showed similar changes: expanded predentin and thin dentin in both Dmp1-null and Dmp1 mutant mice compared with control mice (Fig. 2F). The double-labeling assay also showed similar reductions in dentin formation rate and diffused labeling in both Dmp1-null and Dmp1 mutant mice (Fig. 2G). Lastly,
both Dmp1-null and mutant mice showed similar defects in condyle formation, with expanded hypertrophic chondrocytes in condyles (Fig. 2H, I). Taken together, all the assays just described showed similar defects in both Dmp1-null and mutant mice, supporting a hypothesis that the delMut DPMP1–targeted transgene recaptures the Dmp1-null dentin phenotype without an apparent sign of enamel defects, although the mutant phenotype is slightly milder than that of null mice.

The delMut DPMP1–targeted transgene recaptures the mild changes in serum FGF-23 and Pi levels

We previously reported that delMut patients display mild changes in FGF-23 (<2-fold changes) and Pi levels (<20% reduction) in comparison with the normal controls. In this study we showed a mild increase in FGF-23 (2- to 3-fold) in delMut mice compared with control (Fig. 3A). Similarly, the change in Pi level also was mild in all three age groups

Fig. 2. The delMut Dmp1 recaptures the mild Dmp1-null dentin phenotype with no change in enamel. (A) In situ hybridization (red staining with green nuclear counterstain) for Dmp1 in the lower first molar in 10-day-old mice. In the heterozygous control (HET), Dmp1 is expressed in odontoblasts (left panels). In Dmp1 knockout (KO) mice, there is no Dmp1 signal (middle panels). In Dmp1-null mice with the deletion mutant (MUT) full cDNA reexpressed in odontoblasts (under control of the 3.6-kb Col1a1 promoter), the MUT expression level is very high (right panels). (B) Radiographs of the first upper molars of HET (left), KO (center), and MUT (right) mice, with enlarged pulp/root canals observed in KO and mutant teeth. (C) Coronal section μCT views obtained from the first lower molars of HET (upper left), KO (upper center), and MUT (upper right) mice, exhibiting thin dentin and porous alveolar bone in KO (more striking) and MUT (milder) teeth. Quantitative μCT data (lower panel) reveal a significant difference between HET and NULL groups (*p < .05 by Student’s t test, n = 4). The MUT group shows the same trend but with no significance compared with the HET group. (D) Backscattered SEM images show that there is no apparent difference in the enamel prism structure and distribution among control (left), KO (center), and MUT (right) groups. (E) 3D μCT images of the first lower molars obtained from these three groups, revealing porous dentin structures in the KO (center) and mutant (right) mice. (F) H&E stains of the first lower molars, revealing a thin dentin layer and an enlarged predentin layer in KO (center) and MUT (right) mice. (G) Fluorochrome double-labeled sections of the lower first molars, revealing reduction of the dentin mineralization rate plus diffused labeling lines in KO (center) and MUT (right) mice. (H, I) The abnormalities of condyle formation in KO (center) and MUT (right) mice as documented with radiographs (F) and safranin O assays (I).
Roles of DMP1 recombinant proteins in activation of MAPK signaling vary

Recently, Wu and colleagues (http://iadr.confex.com/iadr/2008Dallas/techprogram/abstract_101678.htm) showed that DMP1 targeted to v8-integrin and activated the MAPK-Erk and Jnk-AP1 signaling pathways in vitro. To address the molecular mechanism by which DMP1 or mutant DMP1 regulate cell signaling, we compared their efficiency in activation of MAPK signaling in an odontoblast cell line. As shown in Fig. 4B, all these recombinant proteins activated phosphorylated ERK. However, the effect of the 57-kDa fragment lasted for over 30 minutes, the full-length protein effect lasted for approximately 10 minutes, and the delMut protein effect lasted for only 5 minutes (see “Discussion” for details).

Odontoblast cells play a role in regulation of FGF-23 expression in vivo

FGF-23 has been demonstrated to be a critical physiologic and pathophysiologic factor in control of phosphate homeostasis in normal and several hypophosphatemic diseases. Previously, we showed that FGF-23 is expressed mainly in osteoblasts in normal bone and sharply increased in Dmp1-null osteocytes. To address whether the odontoblast cells play a role in FGF-23 regulation, we first compared Fgf23 mRNA levels in newborn primary calvarial cells and pulp cells using real-time RT-PCR and showed a roughly 3-fold higher level in pulp cells than in calvarial cells (Fig. 5A). Next, we tested the expression pattern of Fgf23 mRNA in 10-day-old odontoblasts using an in situ hybridization assay. As shown in Fig. 5B, the basal level of Fgf23 mRNA in control odontoblast cells is much higher than that in bone cells. Second, we showed that the level of Fgf23 mRNA was sharply increased in both Dmp1-null osteocytes and odontoblasts, although the changes in the Dmp1-null osteocytes were more striking than those in the Dmp1-null odontoblasts (Fig. 5C). Third, we retargeted expression of WT Dmp1 in both null osteoblast/osteocyte and odontoblast cells by crossing transgenic mice harboring Dmp1 driven by the 3.6-kb Col1a1 promoter to Dmp1-null mice (Fig. 5D). The level of Fgf23 mRNA was returned to the control level in the rescued cells. Lastly, retargeting Dmp1 in the Dmp1-null odontoblast cell by the Dspp promoter that is activated mainly in odontoblast cells reduced the Fgf23 level in the Dmp1-null tooth cell but not in the null bone cell (Fig. 5E). Taken together, this information suggests that odontoblast cells may play in control of FGF-23 level in a pathologic condition. However, this role might be very limited in comparison with the role of osteocytes.

Loss or overexpression of Dmp1 has no effects on expressions of Phex mRNA in odontoblast cells in vivo

Both Dmp1 and Phex are coexpressed in bone and tooth. Deletions of either gene in mice or mutations of DMP1 or PHEX in human patients display an identical hypophosphatemic rickets phenotype. It has long been thought that there might be interactions between PHEX and DMP1 in some manner. To address this issue, we first confirmed Phex mRNA expression in odontoblast cells (Fig. 6A). Next, we analyzed Phex expression levels in Dmp1-null odontoblast cells with or without targeted reexpression of Dmp1 in the Dmp1-null odontoblasts. Our results showed that Phex mRNA levels were largely unchanged, excluding the effects of Dmp1 on Phex expression in the odontoblast cell (Fig. 6B–D).

**Discussion**

Here we have used a clinical case and loss, gain, and mutant animal models, as well as a combination of X-ray, μCT, backscattered SEM,
in situ hybridization, cell culture, and Western blot assays, to gain insight into the roles of DMP1 in tooth development. We find that (1) the delMut patient displayed enlarged pulp/root canals, thin dentin, and unexpected defects in enamel formation, which is similar to a dentinogenesis imperfecta III–like phenotype (see below for detail discussion), (2) the targeted expression of the delMut transgene, identical to that discovered in this patient, in the Dmp1-null background lead to a similar but slightly milder tooth phenotype, as observed in Dmp1-null mice, (3) mild changes are seen in serum FGF-23 and Pi levels in delMut mice, (4) Fgf23 mRNA is expressed in control odontoblast cells with a much higher basal level than that in bone cells, (5) Fgf23 mRNA in Dmp1-null odontoblast cells is upregulated, and reexpression of DMP1 in these Dmp1-null cells restores its original level, and (6) the delMut recombinant DMP1 is able to activate MAPK signaling but much less potently than WT DMP1. Overall, these results suggest that the delMut molecule remains a partial DMP1 function. In addition, the DI III–like phenotype observed in the delMut patient may be due to a second mutation or an as-yet-undetermined genetic modifier closely linked to DMP1 or related to the underlying dentin defect itself. The latter explanation is supported by the fact that abnormal dentin mineralization impairs development of the dentin enamel junction, which subsequently can affect enamel formation. Our data also support a hypothesis that odontoblast cells play a role in control FGF-23 regulation during early postnatal development.

Currently, there are two ways to produce a mutant mouse model. The first approach is to generate the targeted mutation to the locus where the endogenous Dmp1 is located by using a classic homologous recombination technique. The second option is to overexpress the mutant Dmp1, under the control of a promoter highly active in bone and dentin, in a wild-type background or in the Dmp1-null background. We chose the latter based on the following: (1) DMP1 is expressed in both hard and soft tissues during developmental processes, and targeting the mutant gene in hard tissue would fit our goal, (2) we have already generated and partially characterized Dmp1-null mice, and generation of transgenic mouse lines harboring the C-terminal mutant (Fig. 1B) would be straightforward with little risk, (3) we have previously successfully rescued the Dmp1-null phenotypes using the full-length Dmp1 cDNA under the control of the Col1a1 promoter, which has the proper spatial-temporal characteristics to overexpress this gene in hard tissues, (4) varieties in DMP1 mutations identified from ARHR patients or the DMP1 molecule with different mutations can be easily adapted into this system by generation of new transgenic mice, and (5) the first option, targeted mutation to the locus where endogenous Dmp1 is located, has much higher risk partly owing to difficulties in homologous recombination and in getting the targeted cell into the germ line.

A significant question raised in this study is why the 1484–1490del mutation leads to much more severe dentin defects plus
Based on our research results and the current literature (listed below), we propose that the deletion $DMP1$ mutation contributes only to part of the dentin phenotype and that there might be another mutation or an as-yet-undetermined acquired gene modifier or other factor. First, the same mutant gene in the $Dmp1$-null background displays a mild dentin phenotype without an apparent defect in enamel (Fig. 2). It is of note that the deletion mutant molecule remains part of $DMP1$ function because this molecule still can activate MAPK signaling, although the effect is less potent (Fig. 4B). Second, even the homozygous $Dmp1$-null mice exhibit only a dentin phenotype with no changes in enamel.(10,29) Third, the heterozygous alleles of the human $DMP1$ mutants (or $Dmp1$-null mice) or overexpression of this $Dmp1$ deletion mutant in the WT background display no apparently abnormal dentin phenotype, excluding a dominant-negative effect on tooth (data not shown). In fact, other deletion

**Fig. 5.** FGF-23 is higher in pulp/odontoblast cells than in bone cells. (A) $Fgf23$ is expressed in newborn pulp/odontoblast cells higher than in bone cells, as shown by real-time RT-PCR. (B) $Fgf23$ is expressed in control odontoblast cells (signal in red) at a much higher level than in bone, as shown by an in situ hybridization assay. (C) A sharp increase in both Dmp1 KO osteocyte and odontoblast cells. (D, E) Changes in $Fgf23$ mRNA in Dmp1-null osteocytes and odontoblast cells, where the murine Dmp1 cDNA mouse is reexpressed under control of the 3.6-kb Col1a1 promoter (for both bone cells and odontoblast cells, D) or under control of the Dspp promoter (for expression in odontoblast cells only, E). $Fgf23$ mRNA levels are reduced in both KO odontoblast cells, where DMP1 is reexpressed (D, E). Note that $Fgf23$ mRNA level is reduced only in the Col1a1 DMP1 bone cells but not in the Dspp DMP1 bone cells.

**Fig. 6.** Loss of DMP1 or targeted reexpression of DMP1 has little effects on Phex expression in odontoblast cells. (A) Phex is expressed in control odontoblast cells (signal in red), as shown by an in situ hybridization assay. (B–D) Deletion of DMP1 (B) or reexpression of DMP1 (C, D) has little effects on Phex expressions in odontoblast cells.
mutant individuals from the same family display no DI III–like phenotype. Note that this deletion mutation patient manifested hypocalcemia in infancy that was suspected to have resulted from vitamin D deficiency. This nutritional deficiency was treated effectively. Whether the early nutritional deficiency affected enamel development in this patient remains unknown. Lastly, an ARHP kindred family with three affected individuals, in which a novel homozygous frame-shift mutation (c.485Tdel; p.Glu163ArgfsX53) in exon 6 led to a premature stop codon, was reported. These three patients showed a mild dentin defect with little change in enamel. These data are in agreement with our mutant mouse data.

The next question is, What caused the dentinogenesis imperfecta III–like phenotype in the delMut patient (Fig. 2D)? It is known that the most common gene mutation that leads to dentinogenesis imperfecta is the DSPP gene, whose mutations could lead to a dominant dentinogenesis imperfecta II or III phenotype. However, we do not believe that a DSPP gene mutation is likely involved because other ARHR individuals do not show such severe tooth phenotypes. Our current speculation is that the DMP1 deletion mutation triggers changes in the adjacent locus that result in an as-yet-undetermined acquired gene modification. This patient also had vitamin D deficiency in infancy, as discussed, which may have had an effect.

Another possibility for the phenotype difference is that it is due to species differences between humans and mice. One example is DSPP mutations. In humans, heterozygous DSPP mutations display a dominant pathologic phenotype such as a dentinogenesis imperfecta syndrome. On the other hand, there is no apparent phenotype in heterozygous Dsp-null mice, and the dentin defects occur only in homozygous mice.

There is also a spatial-temporal difference in the endogenous DMP1 promoter activity necessarily functional in the human population compared with the exogenous, randomly inserted Col1a1-mutant Dmp1 transgene used in mice. In other words, we chose a transgenic animal approach (rather than a targeted knock-in) and used the Col1a1 promoter (rather than a Dmp1 promoter), and the promoter activity is necessarily different in these mutant animals. The targeted-insertion approach was not used here but may have given a phenotype in mice more closely resembling that of the human population. The dentin abnormalities themselves may affect enamel formation, yet another potential cause for the abnormal enamel findings in this patient.

A final intriguing issue is that expressions of FGF-23 (a newly discovered factor for control of phosphate reabsorption in the kidney) in odontoblast cells may contribute to phosphate homeostasis regulation during early postnatal development. It is well documented that FGF-23 is released mainly from bone cells. Here, both in vitro and in vivo data showed that the level of Fgf23 mRNA in odontoblasts is much higher than that in bone cells (Fig. S4). Note that mouse molars are fully mature at the age of approximately 8 weeks, when the odontoblast cells are no longer active. This may explain in part why the serum level of FGF-23 is higher (~350 pg/mL) in 2-week-old pups than in 7-week-old mice (~100 pg/mL; Dr. Baozhi Yuan, University of Wisconsin–Madison, personal communication). Furthermore, loss of Dmp1 leads to an upregulation of Fgf23, and overexpression of Dmp1 in the null background results in downregulation of Fgf23 (Fig. S8–D). Taken together, these findings support a hypothesis that the odontoblast cell, as an endocrine cell, may contribute to FGF-23 regulation during early postnatal development. However, the odontoblast mass is much smaller than that of bone cells. This regulation of P, homeostasis is likely very limited.

In summary, the successful generation and characterization of a ARHR delMut model provides a powerful tool for studies of the pathophysiologic process of this disease. Our initial study suggests that DMP1 mutations are responsible for the defects in dentinogenesis and that the severe defect in both dentin and enamel in the delMut patient is likely due to an as-yet-undetermined acquired gene modifier or other unidentified factor. Our studies on expression patterns of FGF-23 in odontoblast cells support a new notion that odontoblasts participate in control of FGF-23 expression during early postnatal development.

Disclosures
All the authors state that they have no conflicts of interest.

Acknowledgments
Support for this research was provided by Grants DE015209, AR051587 (to JQF), and DE005092 (to CQ) from the NIH and the Genzyme Renal Innovations Program (to JQF). LMW is supported by a New Investigator Award from the Canadian Institutes for Health Research (CIHR) and a Career Enhancement Award from the Canadian Child Health Clinician Scientist Program.

References
1. Yu X, White KE. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev. 2005;16:221–232.
2. Mejia-Gaviria N, Gil-Pena H, Coto E, Perez-Menendez TM, Santos F. Genetic and clinical peculiarities in a new family with hereditary hypophosphatemic rickets with hypercalcemia: a case report. Orpha-net J Rare Dis. 2010;5:1.
3. Jaureguberry G, Carpenter TO, Forman S, Juppner H, Bergwitz C. A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalcemia in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPiIIc. Am J Physiol Renal Physiol. 2008;295:F371–379.
4. Ichikawa S, Sorenson AH, Imel EA, Friedman NE, Gertner JM, Econs MJ. Intrinsic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalcemia. J Clin Endocrinol Metab. 2006;91:4022–4027.
5. Lorentz-Depiereux B, Benet-Pages A, Eckstein G, et al. Hereditary hypophosphatemic rickets with hypercalcemia is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet. 2006;78:193–201.
6. Tieder M, Modai D, Shaked U, Samuel R, Arie R, Halabe A, Maor J, Weissgarten J, Averbukh Z, Cohen N, et al. “Idiopathic” hypercalcemia and hereditary hypophosphatemic rickets. Two phenotypic expressions of a common genetic defect. N Engl J Med. 1987;316:125–129.
7. Feng QJ, Huang H, Lu Y, Le X, Xie Y, Tsutsui TW, Kunieda T, Castronio T, Scott G, Bonevald LB, Mishina Y. The Dentin matrix protein 1 (Dmp1) is specifically expressed in mineralized, but not soft, tissues during development. J Dent Res. 2003;82:776–780.
8. Ling Y, Rios HF, Myers ER, Lu Y, Feng QJ, Boskey AL. DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res. 2005;20:2169–2177.
9. Ye L, Mishina Y, Chen D, Huang H, Dallas SL, Dallas MR, Sivakumar P, Kunieda T, Tsutsumi TW, Boskey A, Bonewald LF, Feng JQ. Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype. J Biol Chem. 2005;280:6197–6203.

10. Ye L, MacDougall M, Zhang S, Xie Y, Zhang J, Li Z, Lu Y, Mishina Y, Feng JQ. Deletion of dentin matrix protein-1 leads to a partial failure of maturation of predentin into dentin, hypomineralization, and expanded cavities of pulp and root canal during postnatal tooth development. J Biol Chem. 2004;279:19141–19148.

11. Qin C, D’Souza R, Feng JQ. Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis. J Dent Res. 2007;86:1134–1141.

12. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SL, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310–1315.

13. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenblatt J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Kaiser SM, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Muscatelli F, Vittori S, Mazzini L, Lipp J, Anselmo AL, Cappellino F, Lattuada C, De Vivo DC, Bonefeld-Jorgensen EC. Identification of a novel dentin matrix protein-1 (DMP-1) mutation and dental anomalies in a kindred with autosomal recessive hypophosphatemia. J Bone Miner Res. 2002;43:216.

14. Qin C, Brunn JC, Cook RG, Orkiszewski RS, Malone JP, Veis A, Butler WT. Evidence for the proteolytic processing of dentin matrix protein 1. Identification and characterization of processed fragments and cleavage sites. J Biol Chem. 2003;278:34700–34708.

15. Priam F, Ronco V, Locker M, Boud K, Bonnefoix M, Duchene T, Bitard J, Wurtz T, Kellermann O, Goldberg M, Poliard A. New cellular models for tracking the odontoblast phenotype. Arch Oral Biol. 2005;50:271–277.

16. Feng JQ, Ye L, Spaiv A. Do osteocytes contribute to phosphate homeostasis? Curr Opin Nephrol Hypertens. 2009;18:285–291.

17. Yu B, Souza R, MacDougall M, Feng JQ. Dentin sialophosphoprotein knockout mouse teeth display widened predentin zone and develop defective dentin mineralization similar to human dentinogenesis imperfecta type III. J Biol Chem. 2003;278:24874–24880.